July 24th, 2023 - Manchester, CT - DIANT® Pharma Inc. is excited to announce the US Food and Drug Administration’s recent acquisition of the DIANT® LiFT system. The DIANT® LiFT system (https://diantpharma.com/the-diant-lift-system/) is GMP-capable equipment designed for the continuous manufacturing of lipid and polymer-based nanoparticles. In addition to providing the FDA with a high-throughput nanoparticle processing system that is scalable from R&D to commercial manufacturing, the DIANT® equipment also comes with integrated inline/online PAT that can monitor and control the process. DIANT’s goal with PAT integration is to advance both the analytical and output standards across future forms of continuous manufacturing.
DIANT® technology was originally designed to synthesize liposomes and load small molecules at high throughput. However, in 2020 at the onset of the Covid 19 pandemic, the DIANT® technology was adapted to meet the growing and future demands that will be present in nucleic acid therapy via lipid nanoparticle delivery.
The FDA will install and operate this piece of equipment in their Beltsville, MD facility.
About
DIANT® Pharma Inc. (Manchester, CT USA) was founded in 2019 and has developed continuous processing technology for nanoparticles. DIANT® is dedicated to bringing advanced, continuous manufacturing technology to the market and to providing R&D services. Their proprietary, continuous manufacturing system for nanoparticles has a wide array of applications within the pharmaceutical space. (https://diantpharma.com/)
DIANT® provides a continuous manufacturing platform as a turnkey solution for the development and production of nanoparticles for therapeutics and vaccines.
Media Contact:
Gosia Lankosz
Marketing Manager, DIANT Pharma Inc.
Lankosz@diantpharma.com
